연구 및 보고서

Oncogenic Therapeutics reports that 자큐보 (자스타프라잔시트르산염) improved GERD symptoms and was well tolerated in a real‑world study of over 5,500 patients, including those switched from PPIs.

Yuhan Corp. has signed an MOU with Daegu‑Gyeongbuk Advanced Medical Industry Promotion Foundation (K‑MediHub) to broaden joint new‑drug projects and share research infrastructure.

In the global Phase 3 CARES-310 study, HLB's riboceranib‑camrelizumab combo achieved a median overall survival of 21.5 months in patients under 50, outperforming sorafenib's 15.2 months, with consistent benefit across age groups.

GC녹십자웰빙 announced that its exclusive drug candidate RZL-012 achieved primary efficacy and safety endpoints in a pivotal Phase 3 trial in China involving 480 adults with submental fat.

Korean Prime Pharma received approval to start a Phase‑1 exploratory study of its cetirizine orally disintegrating tablet (KPP‑2603‑T) in six healthy adults.

A Danish research team projects worldwide type 1 diabetes patients will increase from 9.4 million to about 12.1 million by 2049, a 30% rise, with new cases up 14%.

Research shows individuals with parents who lived past 100 have significantly lower risks of death, heart disease and hypertension.

Patients with high glucose, low body weight or prior ketoacidosis on SGLT2 inhibitors face higher serious adverse event risk, especially during infection or acute illness.

Novartis reported that its BTK inhibitor remibrutinib (Rhapsido) met primary and key secondary endpoints in two Phase 3 trials for relapsing MS, without liver safety concerns, outperforming Sanofi's Aubagio.

Altheogen announced an exclusive option and license agreement with Novartis for its ALT‑B4 hyaluronidase platform, marking its fourth such deal this year as pharma firms shift from IV to subcutaneous formulations.

Ewha Aortic Vascular Hospital and imaging firm FlowNix have agreed to jointly develop an integrated solution covering the full clinical workflow for aortic patients, from diagnosis to long‑term follow‑up.

SK Biopharm has installed 128 Nvidia B200 AI accelerators, delivering 576 PFLOPS to boost AI-driven drug candidate discovery and translational research.